| Institution: | 1. Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA;2. Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA;3. Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway;4. Department of Neurology, St. Olav's Hospital, Trondheim, Norway;5. Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA;6. Department of Neurology, School of Medicine, University of Miami, Miami, Florida, USA;7. Division of Neurology, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan, Canada;8. Department of Neurology, Royal Victoria Hospital, Belfast, Ireland;9. Department of Neurology, Mater Misericordiae Hospital, Dublin, and University, College Dublin Conway Neuroscience Investigator, Ireland;10. Department of Neuropathology, Mayo Clinic, Jacksonville, Florida, USA |
| Abstract: | Genetic variation in fibroblast growth factor 20 (FGF20) has been associated with risk of Parkinson's disease (PD). Functional evidence suggested the T allele of one SNP, rs12720208 C/T, altered PD risk by increasing FGF20 and α‐synuclein protein levels. Herein we report our association study of FGF20 and PD risk in four patient‐control series (total: 1,262 patients and 1,881 controls), and measurements of FGF20 and α‐synuclein protein levels in brain samples (nine patients). We found no evidence of association between FGF20 variability and PD risk, and no relationship between the rs12720208 genotype, FGF20 and α‐synuclein protein levels. © 2009 Movement Disorder Society |
